PHS
HRTX icon

Pekin Hardy Strauss’s Heron Therapeutics HRTX Stock Holding History

Pekin Hardy Strauss’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.8K Hold
15,992
– – ﹤0.01% 477
2025
Q4 		$20.8K Buy
+15,992
New +$19.7K ﹤0.01% 453
2024
Q4 		– Sell
-15,170
Closed -$30.2K – 372
2024
Q3 		$30.2K Sell
15,170
-10,000
-40% -$23.9K ﹤0.01% 339
2024
Q2 		$88.1K Sell
25,170
-6,000
-19% -$18.4K 0.01% 316
2024
Q1 		$86.3K Sell
31,170
-5,300
-15% -$13.3K 0.01% 316
2023
Q4 		$62K Sell
36,470
-22,625
-38% -$24.9K 0.01% 297
2023
Q3 		$60.9K Sell
59,095
-47,050
-44% -$67K 0.01% 302
2023
Q2 		$123K Sell
106,145
-465,560
-81% -$830K 0.01% 295
2023
Q1 		$863K Sell
571,705
-150
-0% -$376 0.12% 154
2022
Q4 		$1.43M Sell
571,855
-71,260
-11% -$230K 0.2% 113
2022
Q3 		$2.71M Buy
643,115
+2,275
+0.4% +$8.9K 0.43% 65
2022
Q2 		$1.79M Buy
640,840
+42,575
+7% +$171K 0.25% 96
2022
Q1 		$3.42M Buy
598,265
+28,025
+5% +$205K 0.43% 60
2021
Q4 		$5.21M Buy
570,240
+126,855
+29% +$1.3M 0.7% 37
2021
Q3 		$4.74M Sell
443,385
-333,315
-43% -$4.06M 0.68% 35
2021
Q2 		$12.1M Buy
776,700
+255,895
+49% +$4.07M 1.68% 8
2021
Q1 		$8.44M Buy
520,805
+54,368
+12% +$969K 1.33% 18
2020
Q4 		$9.87M Sell
466,437
-128,476
-22% -$2.23M 1.71% 9
2020
Q3 		$8.82M Buy
594,913
+142
+0% +$2.22K 1.8% 9
2020
Q2 		$8.75M Buy
594,771
+6,039
+1% +$99.2K 1.93% 10
2020
Q1 		$6.91M Buy
588,732
+98,772
+20% +$1.86M 1.55% 15
2019
Q4 		$11.5M Buy
+489,960
New +$10.8M 1.89% 14

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Pekin Hardy Strauss's HRTX Position: Q1 2026 in Review

Pekin Hardy Strauss held its Heron Therapeutics (HRTX) position steady in Q1 2026 at 15,992 shares worth $12.8K. The position accounts for ﹤0.01% of the portfolio, ranked #477.

Pekin Hardy Strauss first reported a position in HRTX in Q4 2019 and has held it in 22 quarters since. The position peaked at $12.1M in Q2 2021. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Pekin Hardy Strauss held 15,992 shares of Heron Therapeutics worth $12.8K as of Q1 2026.
  • Pekin Hardy Strauss left its Heron Therapeutics share count unchanged in Q1 2026.
  • Heron Therapeutics made up ﹤0.01% of Pekin Hardy Strauss's portfolio in Q1 2026, its #477 holding.
  • Pekin Hardy Strauss first reported a position in Heron Therapeutics in Q4 2019 and has held it in 22 quarters since.
  • Pekin Hardy Strauss's Heron Therapeutics position peaked at $12.1M in Q2 2021.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Pekin Hardy Strauss's 13F filing for Q1 2026, filed 7 May 2026.